Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

ibsa farmaceutici italia s.r.l. - praparati di tiroide - praparati di tiroide

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, polmone non a piccole cellule - altri agenti antineoplastici, inibitori della proteina chinasi - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

om pharma suisse sa - escherichia coli viva (souche: nissle 1917) - capsule - escherichia coli viva (souche: nissle 1917) 2.5-25 u. mia, maltodextrinum, glycerolum 3.09-15.47 mg, talco, macrogolum 4000, triethylis citras, acidi methacrylici e methylis methacrylatis polymerisatum 1:1, lacca, cera bianca, cera carnauba, e 171, e 172 (giallo), per la capsula, matériel de la capsula: gelatina, acqua purificata. - la colite ulcerosa in fase di remissione - batteri e hefepräparate

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

om pharma suisse sa - escherichia coli viva (souche: nissle 1917) - capsule - escherichia coli viva (souche: nissle 1917) 0.5-5 u. mia, maltodextrinum, glycerolum 1.24-6.19 mg, talco, macrogolum 4000, triethylis citras, acidi methacrylici e methylis methacrylatis polymerisatum 1:1, lacca, cera bianca, cera carnauba, e 171, e 172 (giallo), per la capsula, matériel de la capsula: gelatina, acqua purificata. - la colite ulcerosa in fase di remissione - batteri e hefepräparate

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -

Italia - italiano - Ministero della Salute

ibsa farmaceutici italia srl -